КАПОНИГРО Джордано (US),КУК Весселина (US),МАЙС Анна Хелена (CH),НАУВЕЛАЕРТС Хайди (CH)
申请号：
RU2018146886
公开号：
RU2018146886A
申请日:
2017.06.08
申请国别(地区):
RU
年份:
2020
代理人:
摘要：
The present invention relates to the use of a c-Raf inhibitor for use in the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK). The present invention also relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that binds to Programmed Death 1 (PD-1), and (b) a c-Raf inhibitor or pharmaceutically acceptable salt thereof. The present invention also relates to such a combination for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a solid tumor that harbors Mitogen-activated protein kinase (MAPK) alteration and a commercial package comprising such a combination.
